A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients
Authors
Keywords
-
Journal
THERAPEUTIC DRUG MONITORING
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-09-27
DOI
10.1097/ftd.0000000000001128
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development and Validation of a Novel LC-MS/MS Method for a TDM-Guided Personalization of HSCT Conditioning with High-Dose Busulfan in Children
- (2023) Alessia Cafaro et al. Biomedicines
- Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
- (2021) Athimalaipet V. Ramanan et al. Trials
- A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots
- (2021) Federica Pigliasco et al. Biomedicines
- A Hydrophilic Interaction Liquid Chromatography–Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats
- (2020) Essam Ezzeldin et al. MOLECULES
- Potential drug–drug interactions associated with drugs currently proposed for COVID‐19 treatment in patients receiving other treatments
- (2020) Florian Lemaitre et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: Application to critically ill pediatric patients
- (2020) Sebastiano Barco et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study
- (2020) Xia Zhao et al. Clinical Pharmacology in Drug Development
- LC-MS/MS based quantification of nine antiepileptic drugs from dried sample spots device
- (2019) Annachiara D’Urso et al. THERAPEUTIC DRUG MONITORING
- Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring
- (2019) Dora Koller et al. TALANTA
- Baricitinib: A Review in Rheumatoid Arthritis
- (2018) Zaina T. Al-Salama et al. DRUGS
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- High throughput routine determination of 17 tyrosine kinase inhibitors by LC–MS/MS
- (2018) Camille Merienne et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic drug monitoring and tyrosine kinase inhibitors
- (2016) Pauline Herviou et al. Oncology Letters
- Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
- (2014) Huixin Yu et al. CLINICAL PHARMACOKINETICS
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search